PD2M Emerging Modalities Technical Program | AIChE

PD2M Emerging Modalities Technical Program

1:00 PM - 1:05 PM Opening Remarks
1:05 PM - 2:15 PM SESSION 1: Peptide Therapies
1:05 PM - 1:25 PM Brad Pentelute, MIT
1:25 PM - 1:45 PM

Kevin Seibert, Eli Lilly

Developing a Novel Platform for Synthetic Peptide Manufacture Using Continuous Synthesis Methodologies

1:45 PM - 2:05 PM Joint Q&A
2:05 PM - 2:15 PM "Coffee" Break
2:15 PM - 3:25 PM SESSION 2: RNA Therapies
2:15 PM - 2:35 PM Michelle Lynn Hall, Eli Lilly
2:35 PM - 2:55 PM

Janine Tom, Amgen

siRNA as an Emerging Modality

2:55 PM - 3:15 PM Joint Q&A
3:15 PM - 3:25 PM "Coffee" Break
3:25 PM - 4:25 PM SESSION 3: Cell and Gene Therapies
3:25 PM - 3:45 PM Jennitte Stevens, Amgen
3:45 PM - 4:05 PM

Nathalie Clement University of Florida

From pioneering rAAV to large-scale manufacturing for gene therapy trials

4:05 PM - 4:25 PM Joint Q&A
4:25 PM - 4:30 PM Wrap-up Comments